Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	9.04B
Revenue (ttm)	1.15B
Net Income (ttm)	300.04M
Shares Out	386.86M
EPS (ttm)	0.76
PE Ratio	30.78
Forward PE	26.46
Dividend	0.30 (1.27%)
Ex-Dividend Date	Jun 3, 2025

Volume	4,237,703
Average Volume	12,341,344
Open	24.09
Previous Close	23.36
Day's Range	23.20 - 24.09
52-Week Range	17.55 - 28.79
Beta	0.70
RSI	42.15
Earnings Date	Oct 21, 2025

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, sele...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,144
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.